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Arsenic Trioxide (ATO) has shown remarkable efficacy for the treatment of multiple myeloma (MM). However, the
mechanism by which ATO exerts its inhibitory effect on the proliferation of myeloma cells remains to be clarified.
We study the inhibitory effect of ATO at various concentrations on the proliferation of the myeloma cell line RPMI
8226 and discussed the molecular mechanism of ATO on myeloma cell line. Our results proved that ATO had a
significant dose-dependent and time-dependent inhibitory effect on the expressions of the Notch receptor
(Notch1) and Notch ligand (Jag2). Data from the real-time PCR assay showed that the mRNA expression levels of
the Jag2 gene and its downstream gene Hes1 were both significantly down-regulated after the myeloma cells were
treated with ATO while the expression of the tumor suppressor gene PTEN was up-regulated. These results
elucidated the molecular mechanism underlying the ATO mediated inhibition of myeloma cell proliferation. This is
the first report on the anti-myeloma activity in myeloma cells through inhibition of the Notch signaling pathway.
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Multiple myeloma (MM) is a hematologic malignancy
that results from clonal proliferation of plasma cells in
the bone marrow. Although major advances have been
made in the treatment of MM in the recent years, MM
remains incurable mostly because of the development of
drug resistance [1-5]. Therefore, new therapeutic strat-
egies are needed to improve patient outcome.
Arsenic Trioxide (ATO) has been demonstrated the
efficacy and safety treatment for acute promyelocytic
leukemia (APL), Preclinical in vitro and in vivo studies
showed also that ATO has antimyeloma effects both as a
single agent and in combination with other antimyeloma
agents [6-9], in patients with relapsed MM refractory,
ATO combination therapies with melphalan, thalidomide,
and bortezomib have shown promising results [10,11].
Currently, the effects mechanism of ATO has been stud-
ied extensively on myeloma, Hayashi reported ATO in-
duces apoptosis of MM cells via caspase-9 and overcomes* Correspondence: quanyilu@hotmail.com
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reproduction in any medium, provided the orthe protective effect of IL-6 in the BM milieu by inhibiting
JAK-STAT survival signaling, ATO reduces tumor necrosis
factor (TNF) a-induced adhesion to bone marrow stromal
cells (BMSCs) and the resultant induced secretion of cyto-
kines (IL-6 and VEGF) that promote MM cell growth, sur-
vival, and migration [12], Wu reported that ATO can
mediated growth inhibition of myeloma cells through in-
trinsic signaling pathway activation [13], but the precise
the mechanism is still unclear.
Notch signaling influences multiple processes that
govern normal morphogenesis, apoptosis, and cellular
proliferation. This signaling is initiated by binding of a
Notch ligand to the extracellular domain of the Notch
receptor. Notch ligands include Delta and Jagged (Jag),
and 4 members belong to the Notch family of receptors
(Notch1 to Notch4) [14,15]. There is ample evidence
linking Notch and hematologic malignancies, including
Hodgkin and non-Hodgkin lymphomas, subsets of acute
myeloid leukemia, and B-cell chronic lymphoid leukemia
[16-18]. Inhibition of Notch expression by antisense
retrovirus or pharmacologic block of γ-secretase activity
has a marked antineoplastic effect in Notch-expressing
transformed cells in vitro and in xenograft models [19,20].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cycling in confluent fibroblasts susceptible to density-
dependent inhibition of cell division and therefore may
contribute to neoplastic transformation, Jag2 induces the
secretion of interleukin-6 (IL-6), vascular endothelial
growth factor and insulin-like growth factor [21]. These
results indicated an important role of Notch signaling
(Jag2) in the survival and growth of myeloma cells.
Thus, Jag2 might be a new therapeutic target for mye-
loma treatment.
Although ATO has been studied as potential anti-
myeloma treatment, we don’t know whether ATO could
inhibits the proliferation of myeloma cell through Notch
signaling pathway, in this study we examined ATO ex-
erts anti-myeloma effects involving in activity toward
Notch signaling pathway, our discovery supported that
ATO decreased activity of Notch signaling in myeloma
cell line and which may provide a novel molecular basis
and rationale for the use of ATO in MM treatment.
Materials and methods
Cells and reagents
Myeloma cell line RPMI8226 was bought from Shanghai
cell bank of Chinese Academy of Sciences, Cells were cul-
tured in RPMI 1640 medium (Sigma–Aldrich, St. Louis,
MO, USA) supplemented with 10% heat-inactivated fetal
bovine serum (FBS), 100 U/mL penicillin, 100 mg/mL
streptomycin, and 2 mmol/L lglutamine at 37°C in hu-
midified air containing 5% carbon dioxide. Culture
medium was replaced every 3 days. ATO power was pur-
chased from Sigma Chemical Company and stored at
room temperature, ATO power was dissolved in 1.0 N
NaOH and resulted in a 0.25 mM stock solution, the ATO
solution was diluted in culture media just before use. All
experiments were conducted with cells in logarithmic
phase. For Western blot, mouse monoclonal antibodies
against Notch-1 and Jag-2 (Santa Cruz, CA) the control
cell line is lymphocytes from healthy volunteer. The ex-
perimental procedures were performed within the Xiamen
University Medical Research Council guidelines and were
approved by Zhongshan Hospital Ethics Committees. Pa-
tients provided informed consent according to the Declar-
ation of Helsinki.
MTT assay and flow cytometry
Cells were treated with various concentrations of ATO
for 48 h.
3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bro-
mide (MTT) dye was added during the last 4 h of incuba-
tion. Insoluble formazan complexes were solubilized using
dimethyl sulfoxide (DMSO), and absorbance was measured
at 540 nm using a Benchmark Plus microplate spectropho-
tometer (Bio-Rad, Hercules, CA). Each measurement was
performed in triplicate and repeated at least once.Cell cycle analysis was performed using a Becton
Dickinson FACS flow cytometer according to the meth-
ods described previously [22]. Apoptosis of myeloma cells
was detected by Annexin annexin V-PE/7-AAD staining.
A total of 10,000 events were acquired and analyzed using
a Becton Dickinson FACS flow cytometer.
Western blot analysis
Cell lysates and total protein concentration was mea-
sured with the BCA Protein Assay Kit (Pierce Biotech-
nology, Rockford IL,USA). Equal amounts of protein
were subjected to SDS-PAGE and proteins were trans-
ferred to nitrocellulose membranes (GE Healthcare,
USA). The membrane was blocked in PBS containing
5% non-fat milk and 0.1% Tween-20, washed twice in
PBS, and incubated with primary antibody at room
temperature for 2 hours, followed by incubation with
secondary antibody at room temperature for 45 minutes.
Afterward, the proteins of interest were visualized using
ECL chemiluminescence system (Santa Cruz Biotechnol-
ogy, USA).
Real-time polymerase chain reaction
RPMI 8226 cells were maintained in suspension for the in-
dicated periods of time, and total RNA was isolated using
RNA prep pure Blood Kit (Tiangen Biotech, China). First-
strand cDNA was synthesized with 1 μg of RNA using
ReverTra AceW qPCR RT Kit (Toyobo Co. Ltd., Japan)
and random primers according to the manufacturer’s
protocol. Polymerase chain reaction (PCR) was performed
with 2.5 μL of cDNA template using the FS Universal
SYBR Green Master (Roche) and target gene assay mix
containing human Jag2, Hes1, and PTEN sequence-
specific primers. The PCR reaction system consisted of
ROX 25 μL; forward primer, 0.25 μL; reverse primer, 0.25
μL; cDNA, 5 μL; and diethyl phosphorocyanidate (DEPC),
19.5 μL. The final volume of the reaction mixture was 50
μL. We performed amplification using an 18S endogenous
control assay mix (Amersham Life Sciences) as a control.
The PCR conditions were as follows: 1 cycle at 95°C for
10 min, denaturation at 95°C for 15 s, and annealing/
extension at 60°C for 1 min for a total of 40 cycles. PCR
was performed in triplicate for each sample. Cycle num-
bers obtained at the log-linear phase of the reaction were
plotted against a standard curve prepared using serially
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All values are expressed as the mean ± standard deviation
(SD). Statistical analyses were performed using one-way
analysis of variance (ANOVA) performed using the SPSS
statistical software. Probability values of P < 0.05 were con-
sidered statistically significant.
Results
ATO inhibits myeloma cell growth and induces apoptosis
In order to determine the cell proliferation to ATO,
RPMI8226 cell line was treated with drug at the concen-
tration from 1 μM to 20 μM for 48 hours, ATO
inhibited the growth of MM cells in a dose dependent
manner (Figure 1). Fifty percent growth inhibition
(IC50) in RPMI8226 cells at 48 hours was 2.4 μM ATO ,
as determined by MTT assay, and this results demon-
strate ATO inhibits the proliferation of MM cells at the
relatively low concentration in cell line.
We also performed cell cycle analysis of RPMI 8226
cells treated with ATO (5 μM) by flow cytometry. The
results showed that ATO treatment induced an increase
in the number of cells in the G0/G1 phase, but induced
a significant decrease in the number of cells in the S
phase, and a sub-G1 peak appeared, which suggested
apoptosis of the tumor cells (Figure 2).
Next, in order to confirm whether ATO decreased via-
bility of tumor cells and induce apoptosis after treatment
with ATO, Apoptosis of treated cells was measured by
flow cytometry using annexin V-PE/7-AAD staining,
these results demonstrated that ATO induce myeloma
cell apoptosis in dose-dependent (Figure 2A).
ATO inhibits Notch signaling levels in RPMI 8226 cells
To investigate whether a decrease in notch signaling
level could be achieved by ATO treatment in the mye-
loma cells, RPMI 8226 cells was treated with ATO atFigure 1 ATO inhibits myeloma cells growth. RPMI8226 cell was treated
inhibition was measured with the MTT as described in the Methods.various concentrations, the results showed a gradual de-
crease in the expression of Notch1 and Jag2 proteins
after 48 h of incubation. Compared to the blank group,
cells was treatment with 0.5, 2, 5, or 10 μM ATO
showed a statistically significant reduction in the expres-
sion of Notch1 and Jag2 (P < 0.05). The reduction in pro-
tein expression was dose-dependent (Figure 3A).
Furthermore, RPMI 8226 cells treated with 5 μM ATO for
different durations (24, 48, or 72 h) showed a time-
dependent reduction in the expression of Notch1 and Jag2
(Figure 3B).
We also analyzed the effect of treatment with ATO for
24 h on Notch signaling in RPMI 8226 cells using real-
time PCR. Our results showed that the expressions of
the gene encoding the Notch signaling ligand Jag2 and
its specific target gene Hes1 decreased in RPMI 8226
cells, and the downregulation was dose-dependent. The
difference in their expression levels was significant as
analyzed by one-way ANOVA (P < 0.01, Figure 4).
ATO up-regulate PTEN gene expression
We examined the effect of ATO treatment on changes in
the expression levels of the PTEN gene in RPMI 8226 cells
by using real-time PCR. Results showed that treatment with
different concentrations of ATO for 48 h induced an up-
regulation in PTEN gene expression, and the up-regulation
was significantly different from that in the cells of the con-
trol group (P = 0.006). PTEN expression significantly in-
creased after treatment with 10 μM ATO (Figure 5).
Discussion
ATO has been used for refractory myeloma treatment in
china, the precise mechanisms is uncertain, In the this
study, We first demonstrate that ATO inhibits the prolif-
eration of myeloma cells at low concentrations at time-
and dose-dependent fashion, and Notch signal activitywith ATO in different concentrations for 48 hours, cell growth
Figure 2 ATO inhibits the growth and induces apoptosis of RPMI8226 cell. The myeloma cells were cultured 8 and 48 hours with 5 μM
ATO. The cell cycle and cell apoptosis were analysed by flow cytometry. Data are the mean + SD for three replicate measurements. * means
statistical difference was observed between the treated group and control.
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investigations [23]. In several leukemia and lymphoma
cells, some studies have reported that the high concen-
trations of ATO treatment activated the Jun N-terminal
kinase (JNK) and p38, members of stress-activated signal
transduction pathways, and resulted in apoptosis [24,25].
But the relationship between Notch signal and ATO has
not been studied. Our results indicated that down regu-
lation of Notch signal may be one of molecular mechan-
ism and ATO emerged as a promising class of anti-
cancer drugs in myeloma.
PTEN gene mutation, deletion, downregulation, or
malfunction of the protein encoding PTEN have all beenFigure 3 ATO decreased the level of Notch signal expression of RPMI
concentration ATO for 48 h, the expression of Notch1 and Jagged2 w
treated for 24, 48, and 72 hours, the level of Notch1 ,jagged2 expression wfound in a variety of cancers. PTEN-encoding protein
has lipid and protein phosphatase activity, and it can be
phosphorylated as a substrate. PTEN exerts its tumor
suppressor effect by inhibiting the PI3P/AKT pathway
through its lipid phosphatase activity. Previous studies
found that the drug resistance to Notch signal inhibitor
in T lymphoid leukemia patients was associated with
PTEN gene deletion or abnormal expression [26,27].
Further research showed that activation of Notch signal-
ing enabled upregulation of Hes1, a Notch-target gene.
It combine with PTEN promoter, which results in the
deactivation of PTEN, and consequently, in reduction of
PTEN expression and activation of PI3P/AKT pathway,8226 cells, (A) myeloma cell was treated with different
as obviously decreased. (B) with 5 μM ATO, myeloma cell was
ere significantly reduced.
Figure 4 ATO decreased the over expression of Notch signal in RPMI8226 cells detected by real time PCR. With various concentration ATO
(0.5, 5, and 20 μM), myeloma cell was treated for 24 hours, the over expression of Jagged2 and Hes1 was obviously decreased in RPMI8226 cell.
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apoptosis evasion. We observed an inhibitory effect of
ATO on Notch signaling and downregulation of Hes1
expression as well as subsequent upregulation of PTEN
expression. These results suggest that in MM, Notch sig-
naling probably affects PTEN in a manner similar to that
in T lymphoid leukemia, Notch signaling is negatively
correlated to PTEN expression.
In conclusion, this study showed that ATO exerts anti-
myeloma effects by inhibiting Notch signal and resulting
in up-regulation of PTEN expression. The results identify
ATO as a potential treatment for MM patients.Figure 5 ATO regulated the level of PTEN mRNA expression in RPMI8
(0, 0.5, 5 and 10 μM) for 48 hours, PCR results showed that PTEN mRNA exFurthermore, they contribute to the understanding of the
molecular mechanisms underlying the ATO-induced cell
cycle arrest and apoptosis. Although a number of clinical
studies have shown a moderate success of administering
ATO to MM patients. More studies showed a synergic ef-
fect when ATO is administered in combination with other
anti-MM drugs, such as bortezomib, the DNA methyla-
tion inhibitor 5-azacytidine and melphalan [28-30]. The
results in the present study elaborated a novel molecular
mechanism link among ATO and Notch signal, This is the
first time to discover the relationship of ATO and Notch
signal, our data here thus may provide an important226. Myeloma cell were treated with different concentrations ATO
pression was increased in RPMI8226 cell.
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